Pay in 4 interest-free payments of $7.27 Learn more
Ships within 48 hours · Estimated delivery Oct 10 - Oct 15
Tecentriq (atezolizumab) Disease area(s): Oncology Manufacturer(s): Roche 2024 Sales (USD): $4.13 billion Why it sold so well: In 2024, Roches cancer immunotherapy Tecentriq posted global sales of CHF 3.64 billion ($4.13 billion) and was the companys fourth best-selling drug after MS drug Ocrevus, hemophilia treatment Hemlibra and eye drug Vabysmo
Intrauterine insemination
It is not a GLP-1-only agonist, but it is often discussed alongside GLP-1 medications because many of the benefits and side effects overlap
Scheme 6
Log in Ovum AM Vitanica 60 capsules $N/A (MSRP) Already have an account
US$ 20.89
US$ 29.36
US$ 29.00
